Lawrence Davies

1.2k total citations
33 papers, 674 citations indexed

About

Lawrence Davies is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Lawrence Davies has authored 33 papers receiving a total of 674 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 11 papers in Organic Chemistry and 8 papers in Oncology. Recurrent topics in Lawrence Davies's work include Melanoma and MAPK Pathways (10 papers), Biochemical and Molecular Research (8 papers) and Virus-based gene therapy research (6 papers). Lawrence Davies is often cited by papers focused on Melanoma and MAPK Pathways (10 papers), Biochemical and Molecular Research (8 papers) and Virus-based gene therapy research (6 papers). Lawrence Davies collaborates with scholars based in United Kingdom, United States and Tanzania. Lawrence Davies's co-authors include Frank Friedlos, Caroline J. Springer, Richard Marais, Ion Niculescu‐Duvaz, Dan Niculescu‐Duvaz, Lesley Ogilvie, Steven R. Whittaker, Michael Jarman, Stephen M. Stribbling and Richard J. Knox and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Lawrence Davies

33 papers receiving 650 citations

Peers

Lawrence Davies
Rachel Sikorski United States
Mario Guarneri Italy
Jeremy L. Baryza United States
Girija Krishnamurthy United States
Marie Suggitt United Kingdom
Weiwen Ying United States
Reik Löser Germany
Anke Steinmetz France
Takanori Yasukochi Japan
Mark Ruppen United States
Rachel Sikorski United States
Lawrence Davies
Citations per year, relative to Lawrence Davies Lawrence Davies (= 1×) peers Rachel Sikorski

Countries citing papers authored by Lawrence Davies

Since Specialization
Citations

This map shows the geographic impact of Lawrence Davies's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lawrence Davies with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lawrence Davies more than expected).

Fields of papers citing papers by Lawrence Davies

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lawrence Davies. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lawrence Davies. The network helps show where Lawrence Davies may publish in the future.

Co-authorship network of co-authors of Lawrence Davies

This figure shows the co-authorship network connecting the top 25 collaborators of Lawrence Davies. A scholar is included among the top collaborators of Lawrence Davies based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lawrence Davies. Lawrence Davies is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dean, Emma, Udai Banerji, Ion Niculescu‐Duvaz, et al.. (2016). A Phase 1 first-in-human trial to evaluate the safety and tolerability of CCT3833, an oral panRAF inhibitor, in patients with advanced solid tumours, including metastatic melanoma.. Journal of Clinical Oncology. 34(15_suppl). TPS9597–TPS9597. 2 indexed citations
2.
Niculescu‐Duvaz, Dan, Ion Niculescu‐Duvaz, Bart M. J. M. Suijkerbuijk, et al.. (2013). Potent BRAF kinase inhibitors based on 2,4,5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituents. Bioorganic & Medicinal Chemistry. 21(5). 1284–1304. 36 indexed citations
3.
Elkhawad, Maysoon, Lea Sarov‐Blat, Michael Marber, et al.. (2010). Inhibition of p38 Mitogen-Activated Protein Kinase Attenuates Vascular and Systemic Inflammation in Patients with Atherosclerosis as Assessed by 18-F Fluorodeoxyglucose PET-CT. Circulation. 122(4). 211–20. 3 indexed citations
4.
Niculescu‐Duvaz, Dan, Ion Niculescu‐Duvaz, Bart M. J. M. Suijkerbuijk, et al.. (2010). Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffolds. Bioorganic & Medicinal Chemistry. 18(18). 6934–6952. 28 indexed citations
5.
Nourry, Arnaud, Alfonso Zambon, Lawrence Davies, et al.. (2010). BRAF Inhibitors Based on an Imidazo[4,5]pyridin-2-one Scaffold and a Meta Substituted Middle Ring. Journal of Medicinal Chemistry. 53(5). 1964–1978. 18 indexed citations
6.
Zambon, Alfonso, Delphine Ménard, Bart M. J. M. Suijkerbuijk, et al.. (2010). Novel Hinge Binder Improves Activity and Pharmacokinetic Properties of BRAF Inhibitors. Journal of Medicinal Chemistry. 53(15). 5639–5655. 31 indexed citations
7.
Mancini, Laura, Lawrence Davies, Frank Friedlos, et al.. (2009). A novel technique to monitor carboxypeptidase G2 expression in suicide gene therapy using 19F magnetic resonance spectroscopy. NMR in Biomedicine. 22(5). 561–566. 8 indexed citations
8.
Stribbling, Stephen M., Frank Friedlos, Janet L. Martin, et al.. (2000). Regressions of Established Breast Carcinoma Xenografts by Carboxypeptidase G2 Suicide Gene Therapy and the Prodrug CMDA Are Due to a Bystander Effect. Human Gene Therapy. 11(2). 285–292. 42 indexed citations
9.
Niculescu‐Duvaz, Ion, Frank Friedlos, Dan Niculescu‐Duvaz, Lawrence Davies, & Caroline J. Springer. (1999). Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT).. PubMed. 14(6). 517–38. 29 indexed citations
10.
Pedley, RB, Shreya Sharma, G Boxer, et al.. (1999). Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent.. PubMed. 59(16). 3998–4003. 54 indexed citations
11.
Niculescu‐Duvaz, Dan, Ion Niculescu‐Duvaz, Frank Friedlos, et al.. (1998). Self-Immolative Nitrogen Mustard Prodrugs for Suicide Gene Therapy. Journal of Medicinal Chemistry. 41(26). 5297–5309. 29 indexed citations
12.
Knox, Richard J., Frank Friedlos, Michael Jarman, et al.. (1995). Virtual cofactors for an Escherichia coli nitroreductase enzyme: Relevance to reductively activated prodrugs in antibody directed enzyme prodrug therapy (ADEPT). Biochemical Pharmacology. 49(11). 1641–1647. 29 indexed citations
13.
Knox, Richard J., Frank Friedlos, Patrick J. Biggs, et al.. (1993). Identification, synthesis and properties of 5-(aziridin-1-YL)-2-nitro-4-nitrosobenzamide, A novel DNA crosslinking agent derived from CB1954. Biochemical Pharmacology. 46(5). 797–803. 23 indexed citations
14.
Suzutani, Tatsuo, Lawrence Davies, & R. W. Honess. (1993). Kinetic studies of the predicted substrate-binding site of varicella-zoster virus thymidine kinase. Journal of General Virology. 74(6). 1011–1016. 9 indexed citations
15.
Friedlos, Frank, Michael Jarman, Lawrence Davies, Marion P. Boland, & Richard J. Knox. (1992). Identification of novel reduced pyridinium derivatives as synthetic co-factors for the enzyme DT diaphorase (NAD(P)H dehydrogenase (quinone), EC 1.6.99.2). Biochemical Pharmacology. 44(1). 25–31. 41 indexed citations
16.
Davies, Lawrence. (1989). The Synthesis of αβ Imidothymidine Diphospate. Nucleosides Nucleotides & Nucleic Acids. 8(5). 1053–1054. 1 indexed citations
17.
18.
Davies, Lawrence, J. A. Stock, S. Elaine Barrie, Rosanne M. Orr, & Kenneth R. Harrap. (1988). Dinucleotide analogs as inhibitors of thymidine kinase, thymidylate kinase and ribonucleotide reductase. Journal of Medicinal Chemistry. 31(7). 1305–1308. 10 indexed citations
19.
Jones, Terence R., AH Calvert, A.L. Jackman, et al.. (1986). ChemInform Abstract: Quinazoline Antifolates Inhibiting Thymidylate Synthase: Variation of the N10 Substituent.. Chemischer Informationsdienst. 17(6). 3 indexed citations
20.
Davies, Lawrence, P. B. Farmer, Michael Jarman, & J. A. Stock. (1980). Two-Stage Synthesis of 3′-O-Tritylthymidine via Hydrolysis of 3′, 5′-Di-O-tritylthymidine; Comparison with Alternative Methods. Synthesis. 1980(1). 75–76. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rachel Sikorski Breakdown of academic impact, for papers by Mario Guarneri Breakdown of academic impact, for papers by Jeremy L. Baryza Breakdown of academic impact, for papers by Girija Krishnamurthy Breakdown of academic impact, for papers by Marie Suggitt Breakdown of academic impact, for papers by Weiwen Ying Breakdown of academic impact, for papers by Reik Löser Breakdown of academic impact, for papers by Anke Steinmetz Breakdown of academic impact, for papers by Takanori Yasukochi Breakdown of academic impact, for papers by Mark Ruppen
Rankless by CCL
2026